OPDIVO® (nivolumab) + YERVOY® (ipilimumab) Efficacy Data for mNSCLC
Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis - The Lancet Oncology
Immunotherapy Advances - ASCO 2020: Key Lung Cancer Studies - Lung Cancer - 2020 ASCO Annual Meeting - Oncology - Clinical Care Options
ASCO 2022: Five-year survival outcomes with nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) as first-line (1L) treatment for metastatic non–small cell lung cancer (NSCLC): Results from CheckMate 227.
First-line nivolumab + ipilimumab in advanced NSCLC: CheckMate 227 subpopulation analyses in Asian patients - ScienceDirect
ISPOR 2022: Mixture-Cure Modelling of the Overall Survival Outcomes of Patients with Advanced Non-Small Cell Lung Cancer (ANSCLC) Receiving Nivolumab + Ipilimumab in CheckMate-227
Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer | NEJM
CheckMate 568: Efficacy and Biomarker Analysis for Nivolumab and Ipilimumab in NSCLC - ILCN.org (ILCN/WCLC)
Bristol might play a role in front-line lung cancer after all | Evaluate
First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update - ESMO Open
Update Confirms 5-Year Survival Benefit With Dual Immune Checkpoint Blockade in NSCLC
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden | NEJM
Nivolumab Combined with Ipilimumab
First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial - ScienceDirect
OPDIVO® (nivolumab) + YERVOY® (ipilimumab) Efficacy Data for mNSCLC
Rapid Readouts: Three-Year Update From CheckMate 227, Part 1
2021 Midyear Review: Non–Small-Cell Lung Cancer | Personalized Medicine in Oncology
Best Practices: Practical Guidance in Treating Advanced NSCLC with Immunotherapy | Oncology Practice Management
Comparisons between the CheckMate 227 trial and simulation, overall... | Download Scientific Diagram
ESMO 2022: Treatment switching adjustment of overall survival in the CheckMate 227 clinical trial of nivolumab plus ipilimumab versus chemotherapy in first-line treatment of patients with advanced non-small cell lung cancer
First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy in Advanced NSCLC With 1% or Greater Tumor PD-L1 Expression: Patient-Reported Outcomes From CheckMate 227 Part 1 - Journal of Thoracic Oncology
FDA approves immuno-oncology combination as first-line treatment in patients with NSCLC who express positive PD-L1 greater than 1% - Onco Americas
Immunotherapy Advances - ASCO 2020: Key Lung Cancer Studies - Lung Cancer - 2020 ASCO Annual Meeting - Oncology - Clinical Care Options
Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC | Nature Reviews Clinical Oncology
First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in advanced non-small cell lung cancer: a subanalysis of Asian patients in CheckMate 9LA | SpringerLink
